Hikal Limited (NSE: HIKAL) is a leading Indian life sciences company with a global presence. The company specializes in developing and manufacturing intermediates, active pharmaceutical ingredients (APIs), and specialty chemicals for the pharmaceutical, agrochemical, and animal health industries. HIKAL has a strong focus on innovation and quality, which has helped it establish a leading position in the market.
In terms of earnings, Revenue from Operations for Q3 FY23 was ₹538.45 crore, a 6% increase from ₹506.62 crore in the same period last year. The Pharmaceutical segment generated a total of ₹292.18 Crore in revenue, or 54% of the total revenue. The Crop protection segment which reported revenue of ₹248.02 Crore, accounted for the remaining percent of the overall Revenue. The Consolidated Net Profit was ₹26.41 crore, down 41% from ₹45.2 crore in the same quarter last year. This quarter’s earnings per share was ₹2.14.